Androgen receptor inhibitors improved survival in men ages 80 and older with nonmetastatic, castration-resistant prostate cancer in a pooled analysis by the US Food and Drug Administration.
Reuters Health Information
Androgen receptor inhibitors improved survival in men ages 80 and older with nonmetastatic, castration-resistant prostate cancer in a pooled analysis by the US Food and Drug Administration.
Reuters Health Information
